Cell Culture Market is anticipated to expand at a stupendous CAGR of 11.8% through 2033

The global cell culture market is expected to be worth US$ 25.4 billion in 2022 and US$ 29.0 billion in 2023. Furthermore, with rising demand for biopharmaceuticals such as vaccines and stem cells, as well as increased R&D activities, the global cell culture market is expected to grow at a staggering CAGR of 11.8% between 2023 and 2033, achieving a valuation of roughly US$ 88.6 billion by 2033.

As per FMI, the key market drivers during the forecast period are:

• Acceleration in the pace of research and development activities aiding mass production of biopharmaceuticals
• Rising demand for advanced cell culture-based products
• Wide utility across pharmaceutical companies, research institutes, and food development
• Chronic diseases that warrant innovations in biopharmaceuticals
• Rising consumer demand for monoclonal antibodies (mAbs)

Request a report sample to gain compressive insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-14318

Cell Culture Application in Pharma & Health is Key to Market Growth

Currently, innovations are driving the market growth. Because various end-user segments are investing heavily in cell culture research and development, the demand for advanced variants of cell culture products is on the rise. Similarly, there is an increasing need for novel therapeutics like biosimilars that positively impact market prospects.

All these factors have collectively carved out a niche application of cell culture across the pharma and healthcare sector. This is primarily fueled by the consistent rise in cancer, renal diseases, diabetes as well as cardiovascular diseases. With consumer demand for advanced treatment options rising, cell culture can create lucrative avenues for the pharma & healthcare sectors to prosper.

Key Players Need to Find a Way Out of Market Bottlenecks to Aid Growth

In-depth research in cell biology is required for product development. However, this leads warrants the need for heavy investment. To develop high-end products that adhere to high regulatory standards, manufacturers need to invest in high-quality equipment and other inputs. This limits the accessibility of smaller enterprises to the priced cell culture resources. The same applies to research institutes with limited capacities. Even further in the processing steps, manufacturers are required to invest both time and technical expertise for cell harvesting. If key players can navigate these technical bottlenecks, the market could expand even further in the coming years.

Get a Discount on the Report@ https://www.futuremarketinsights.com/request-discount/rep-gb-14318

Key Takeaways from the Report:

• Between 2017 and 2022, the market recorded a CAGR of 13.5%, attaining a valuation of US$ 25.4 billion by 2022.
• During the forecast period, the United States market is projected to expand at a CAGR of 11.6% and reach a valuation of US$ 31.4 billion by 2033.
• Between 2023 and 2033, the United Kingdom market is expected to record a CAGR of 10.9%, to attain a valuation of US$ 3.7 billion by 2033.
• The consumables segment is projected to register a CAGR of 11.4% during the forecast period.
• The biopharmaceutical production segment is anticipated to witness a CAGR of 11.1% during the forecast period.

Key Market Developments:

• In January 2022, Cytiva (Danaher Corporation) announced its collaboration with Nucleus Biologics. This can be an important step towards developing custom culture media for cell as well as gene therapies.
• In February 2022, KromaTiD enhanced its services by venturing into cell and blood culture isolation, and processing, coupled with quality control services

Key Players:

• Danaher Corporation
• Thermo Fisher Scientific
• Becton
• Dickinson and Company
• Corning Incorporated
• Merck KgaA
• PromoCell GmbH
• Sartorius AG

We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-14318

Key Segments

By Product:

• Consumables
  • Sera
  • Media
  • Reagents
  • Vessels
  • Accessories
• Equipment
  • Supporting Equipment
  • Bioreactors
  • Storage Equipment

By Application:

• Biopharmaceutical Production
  • Monoclonal antibodies
  • Vaccines production
  • Other therapeutic proteins
• Diagnostics
  • Drug Screening & Development
    • Tissue Engineering & Regenerative Medicine
  • Cell and gene therapy
• Others

By End User:

• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic Laboratories
• Research & Academic Institutes
• Others

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs